Shanghai InnoStar Bio-tech Co

Shanghai InnoStar Bio-tech Co Earnings Yield

The Earnings Yield of Shanghai InnoStar Bio-tech Co (688710.SS) as of Oct 20, 2026 is -0.50 %. In the previous year, Earnings Yield was 2.42 % — a change of -120.65% (lower).

Earnings Yield

-0.50 %

YoY

-120.65%

Last updated:

Earnings Yield of Shanghai InnoStar Bio-tech Co is 2025 -0.50 % . Earnings Yield of Shanghai InnoStar Bio-tech Co was 2024 2.42 % . It decreases by -120.65% lower compared to the previous year.

The Shanghai InnoStar Bio-tech Co Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2021
1.42 CNY
Jan 1, 2022
2.22 CNY
Jan 1, 2023
3.19 CNY
Jan 1, 2024
2.42 CNY
Jan 1, 2025
-0.50 CNY
The Shanghai InnoStar Bio-tech Co Earnings Yield history
YEAREarnings YieldYoY
-0.50 %-120.65%
2.42 %-24.00%
3.19 %+43.60%
2.22 %+56.13%
1.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai InnoStar Bio-tech Co Stock analysis

What does Shanghai InnoStar Bio-tech Co do? Shanghai InnoStar Bio-tech Co Ltd generates revenue through biopharmaceutical non-clinical research services, primarily targeting pharmaceutical companies and biotech firms. The company offers early drug development evaluation services that develop multiple early toxicity rapid prediction and screening models. Non-clinical research services include non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacodynamic research. Clinical testing and translational research provides analytical methods and data support for clinical pharmacokinetics, efficacy, and safety research of innovative drug projects. The firm's clients are pharmaceutical companies and biotech firms seeking to advance innovative drug projects through non-clinical and clinical research. These clients purchase the company's services to support early drug development, safety evaluation, and translational research needs. The company's focus on biopharmaceutical non-clinical research positions it to serve the growing demand for specialized research services in the life sciences sector. Shanghai InnoStar Bio-tech Co Ltd's service portfolio is structured around three core areas: early drug development evaluation, non-clinical research, and clinical testing and translational research. Each segment provides specialized services that support different stages of drug development, from initial toxicity screening to clinical research support. The company's revenue is derived from these specialized service offerings delivered to pharmaceutical and biotech clients. Shanghai InnoStar Bio-tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai InnoStar Bio-tech Co stock

Earnings Yield of Shanghai InnoStar Bio-tech Co is -0.50 % in 2025.

Earnings Yield of Shanghai InnoStar Bio-tech Co changed from 2.42 % to -0.50 %, representing a -120.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Shanghai InnoStar Bio-tech Co since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Shanghai InnoStar Bio-tech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Shanghai InnoStar Bio-tech Co

All Key Metrics — Shanghai InnoStar Bio-tech Co